HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lei Zheng Selected Research

taspine

5/2014A novel taspine derivative, HMQ1611, suppresses adhesion, migration and invasion of ZR-75-30 human breast cancer cells.
9/2013A novel taspine derivative suppresses human liver tumor growth and invasion in vitro and in vivo.
6/2012A novel taspine derivative, HMQ1611, inhibits breast cancer cell growth via estrogen receptor α and EGF receptor signaling pathways.
1/2012Tas13D inhibits growth of SMMC-7721 cell via suppression VEGF and EGF expression.
11/2011Antitumor activity of taspine by modulating the EGFR signaling pathway of Erk1/2 and Akt in vitro and in vivo.
9/2011Activity of taspine isolated from Radix et Rhizoma Leonticis against estrogen-receptor-positive breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Lei Zheng Research Topics

Disease

231Neoplasms (Cancer)
11/2022 - 01/2002
77Pancreatic Neoplasms (Pancreatic Cancer)
11/2022 - 04/2011
69Adenocarcinoma
11/2022 - 04/2011
47Neoplasm Metastasis (Metastasis)
11/2022 - 10/2010
29Atherosclerosis
05/2021 - 02/2010
24Inflammation (Inflammations)
04/2022 - 09/2006
24Breast Neoplasms (Breast Cancer)
01/2022 - 06/2008
21Hepatocellular Carcinoma (Hepatoma)
07/2021 - 12/2010
15Lung Neoplasms (Lung Cancer)
01/2021 - 01/2014
15Colorectal Neoplasms (Colorectal Cancer)
01/2021 - 01/2011
14Carcinogenesis
01/2022 - 01/2002
14Prostatic Neoplasms (Prostate Cancer)
11/2020 - 06/2012
12Infections
02/2022 - 01/2007
12Carcinoma (Carcinomatosis)
10/2021 - 04/2007
11Atherosclerotic Plaque (Atheroma)
05/2021 - 01/2013
9Wounds and Injuries (Trauma)
01/2022 - 01/2008
9Stomach Neoplasms (Stomach Cancer)
01/2021 - 03/2014
8Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
06/2022 - 12/2013
8Fibrosis (Cirrhosis)
01/2022 - 10/2012
8Colonic Neoplasms (Colon Cancer)
01/2021 - 10/2013
8Glioma (Gliomas)
01/2020 - 02/2008
8Circulating Neoplastic Cells
01/2020 - 12/2015
7Cardiovascular Diseases (Cardiovascular Disease)
05/2021 - 01/2014
7Pituitary Neoplasms (Pituitary Adenoma)
01/2018 - 01/2002
6Body Weight (Weight, Body)
09/2022 - 02/2010
6Alzheimer Disease (Alzheimer's Disease)
08/2022 - 02/2015
6Liver Cirrhosis (Hepatic Cirrhosis)
01/2022 - 01/2017
6Portal Hypertension
01/2022 - 01/2017
6Uterine Cervical Neoplasms (Cancer of the Cervix)
01/2020 - 07/2007
5Sepsis (Septicemia)
10/2022 - 04/2013
5Cognitive Dysfunction
01/2022 - 02/2015
5Myocardial Infarction
09/2021 - 12/2007
5Liver Neoplasms (Liver Cancer)
07/2021 - 01/2012
5Ovarian Neoplasms (Ovarian Cancer)
01/2020 - 10/2009
5Melanoma (Melanoma, Malignant)
01/2020 - 01/2013
4Cholangiocarcinoma
01/2022 - 01/2020
4Necrosis
07/2021 - 02/2013
4Adenoid Cystic Carcinoma (Cylindroma)
03/2021 - 10/2014
4Margins of Excision
01/2021 - 02/2013
4Stroke (Strokes)
01/2021 - 02/2017
4Diabetic Cardiomyopathies
12/2020 - 01/2016
4Hypoxia (Hypoxemia)
11/2020 - 11/2017
4Obesity
10/2020 - 04/2016

Drug/Important Bio-Agent (IBA)

70Biomarkers (Surrogate Marker)IBA
06/2022 - 10/2008
54Proteins (Proteins, Gene)FDA Link
10/2022 - 12/2002
32MicroRNAs (MicroRNA)IBA
04/2022 - 04/2013
30Long Noncoding RNAIBA
06/2022 - 03/2014
24Pharmaceutical PreparationsIBA
09/2022 - 08/2007
21CytokinesIBA
01/2022 - 09/2007
20Immune Checkpoint InhibitorsIBA
05/2022 - 09/2013
20Messenger RNA (mRNA)IBA
11/2021 - 11/2006
20VaccinesIBA
01/2021 - 11/2012
19Biological ProductsIBA
02/2022 - 01/2002
18DNA (Deoxyribonucleic Acid)IBA
11/2022 - 02/2004
17Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2021 - 07/2007
17AntibodiesIBA
10/2020 - 10/2007
14CholesterolIBA
01/2021 - 01/2012
14Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
01/2021 - 09/2013
13GemcitabineFDA Link
11/2022 - 02/2012
13RNA (Ribonucleic Acid)IBA
10/2022 - 02/2008
12AntigensIBA
07/2021 - 12/2009
11Peptides (Polypeptides)IBA
01/2021 - 07/2009
11Cancer VaccinesIBA
10/2020 - 09/2013
9Small Interfering RNA (siRNA)IBA
11/2020 - 10/2009
8Interleukin-6 (Interleukin 6)IBA
04/2022 - 05/2013
7CateninsIBA
01/2021 - 01/2015
7EnzymesIBA
01/2021 - 09/2007
7Annexin A2 (Annexin II)IBA
01/2019 - 04/2011
7Apolipoproteins E (ApoE)IBA
01/2016 - 01/2013
6Hyaluronic Acid (Hyaluronan)IBA
11/2022 - 01/2018
6Nucleic AcidsIBA
09/2022 - 04/2016
6LipopolysaccharidesIBA
09/2022 - 05/2013
6Transcription Factors (Transcription Factor)IBA
01/2021 - 02/2004
6C-Reactive ProteinIBA
12/2020 - 01/2015
6oxidized low density lipoproteinIBA
12/2020 - 04/2014
6Membrane Proteins (Integral Membrane Proteins)IBA
11/2020 - 01/2003
6LigandsIBA
01/2020 - 10/2004
6Protein Isoforms (Isoforms)IBA
11/2015 - 01/2002
6taspineIBA
05/2014 - 09/2011
5Interleukin-8 (Interleukin 8)IBA
04/2022 - 09/2006
5MethyltransferasesIBA
01/2022 - 12/2019
5InterferonsIBA
01/2021 - 01/2015
5LipidsIBA
01/2021 - 02/2013
5Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2020 - 04/2008
5Therapeutic UsesIBA
01/2020 - 12/2016
5InterleukinsIBA
01/2018 - 05/2013
4Programmed Cell Death 1 ReceptorIBA
11/2022 - 01/2020
4Circular RNAIBA
01/2022 - 01/2018
4IntegrinsIBA
11/2021 - 08/2010
4Iodine-125IBA
03/2021 - 10/2014
4Fibroblast Growth Factor 1 (FGF-1)IBA
12/2020 - 02/2016

Therapy/Procedure

94Therapeutics
11/2022 - 02/2011
41Drug Therapy (Chemotherapy)
11/2022 - 10/2008
38Immunotherapy
01/2022 - 01/2012
34Radiotherapy
11/2022 - 02/2011
22Brachytherapy
09/2022 - 03/2008
10Neoadjuvant Therapy
12/2021 - 12/2013
7Precision Medicine
01/2022 - 08/2017
6Aftercare (After-Treatment)
01/2021 - 04/2008
6Microbubbles
12/2020 - 01/2016